
Ralph A Tripp

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3796262/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	ACE2-lgG1 fusions with improved inÂvitro and inÂvivo activity against SARS-CoV-2. IScience, 2022, 25, 103670.	1.9	29
2	Exploring Noncovalent Protease Inhibitors for the Treatment of Severe Acute Respiratory Syndrome and Severe Acute Respiratory Syndrome-Like Coronaviruses. ACS Infectious Diseases, 2022, 8, 596-611.	1.8	6
3	Repurposing Probenecid to Inhibit SARS-CoV-2, Influenza Virus, and Respiratory Syncytial Virus (RSV) Replication. Viruses, 2022, 14, 612.	1.5	6
4	Silver nanotriangle array based LSPR sensor for rapid coronavirus detection. Sensors and Actuators B: Chemical, 2022, 359, 131604.	4.0	35
5	Breakthrough therapy designation of nirsevimab for the prevention of lower respiratory tract illness caused by respiratory syncytial virus infections (RSV). Expert Opinion on Investigational Drugs, 2022, 31, 23-29.	1.9	13
6	Probenecid Inhibits Respiratory Syncytial Virus (RSV) Replication. Viruses, 2022, 14, 912.	1.5	8
7	Isothermal amplification using sequence-specific fluorescence detection of SARS coronavirus 2 and variants in nasal swabs. BioTechniques, 2022, 72, 263-272.	0.8	5
8	The Hypothiocyanite and Amantadine Combination Treatment Prevents Lethal Influenza A Virus Infection in Mice. Frontiers in Immunology, 2022, 13, .	2.2	4
9	Structural basis for ultrapotent antibody-mediated neutralization of human metapneumovirus. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, .	3.3	8
10	Detection of swine influenza virus in nasal specimens by reverse transcription-loop-mediated isothermal amplification (RT-LAMP). Journal of Virological Methods, 2021, 288, 114015.	1.0	4
11	Non anonical autophagy functions of ATG16L1 in epithelial cells limit lethal infection by influenza A virus. EMBO Journal, 2021, 40, e105543.	3.5	36
12	Respiratory Syncytial Virus (RSV) G Protein Vaccines With Central Conserved Domain Mutations Induce CX3C-CX3CR1 Blocking Antibodies. Viruses, 2021, 13, 352.	1.5	17
13	G-Protein-Coupled Receptor and Ion Channel Genes Used by Influenza Virus for Replication. Journal of Virology, 2021, 95, .	1.5	10
14	Intervention Strategies for Seasonal and Emerging Respiratory Viruses with Drugs and Vaccines Targeting Viral Surface Glycoproteins. Viruses, 2021, 13, 625.	1.5	5
15	Dual oxidase 1 promotes antiviral innate immunity. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	3.3	16
16	Innate Antiviral Cytokine Response to Swine Influenza Virus by Swine Respiratory Epithelial Cells. Journal of Virology, 2021, 95, e0069221.	1.5	3
17	Losartan Inhibits SARS-CoV-2 Replication in Vitro. Journal of Pharmacy and Pharmaceutical Sciences, 2021, 24, 390-399.	0.9	12
18	Selinexor, a novel selective inhibitor of nuclear export, reduces SARS-CoV-2 infection and protects the respiratory system in vivo. Antiviral Research, 2021, 192, 105115.	1.9	34

#	Article	IF	CITATIONS
19	Structure, Immunogenicity, and Conformation-Dependent Receptor Binding of the Postfusion Human Metapneumovirus F Protein. Journal of Virology, 2021, 95, e0059321.	1.5	11
20	Small Non-coding RNA Expression Following Respiratory Syncytial Virus or Measles Virus Infection of Neuronal Cells. Frontiers in Microbiology, 2021, 12, 671852.	1.5	0
21	Advances in Vaccine Development. Vaccines, 2021, 9, 1036.	2.1	1
22	Probenecid inhibits SARS-CoV-2 replication in vivo and in vitro. Scientific Reports, 2021, 11, 18085.	1.6	23
23	Reversible disruption of XPO1-mediated nuclear export inhibits respiratory syncytial virus (RSV) replication. Scientific Reports, 2021, 11, 19223.	1.6	6
24	Isothermal amplification and fluorescent detection of SARS-CoV-2 and SARS-CoV-2 variant virus in nasopharyngeal swabs. PLoS ONE, 2021, 16, e0257563.	1.1	11
25	Drug repositioning of Clopidogrel or Triamterene to inhibit influenza virus replication in vitro. PLoS ONE, 2021, 16, e0259129.	1.1	4
26	MicroRNAs affect GPCR and Ion channel genes needed for influenza replication. Journal of General Virology, 2021, 102, .	1.3	0
27	Immunopathology of RSV: An Updated Review. Viruses, 2021, 13, 2478.	1.5	38
28	Pathobiology of Respiratory Syncytial Virus (RSV). Vaccines, 2020, 8, 367.	2.1	0
29	Exosome-mediated human norovirus infection. PLoS ONE, 2020, 15, e0237044.	1.1	8
30	Molecular epidemiology and glycomics of swine influenza viruses circulating in commercial swine farms in the southeastern and midwest United States. Veterinary Microbiology, 2020, 251, 108914.	0.8	6
31	Innate and adaptive immune responses in respiratory virus infection: implications for the clinic. Expert Review of Respiratory Medicine, 2020, 14, 1141-1147.	1.0	15
32	Characterization and Noncovalent Inhibition of the Deubiquitinase and deISGylase Activity of SARS-CoV-2 Papain-Like Protease. ACS Infectious Diseases, 2020, 6, 2099-2109.	1.8	239
33	Peter C. Doherty: A Legacy of Mentoring. Viral Immunology, 2020, 33, 143-144.	0.6	0
34	Emerging small and large molecule therapeutics for respiratory syncytial virus. Expert Opinion on Investigational Drugs, 2020, 29, 285-294.	1.9	14
35	Up-to-date role of biologics in the management of respiratory syncytial virus. Expert Opinion on Biological Therapy, 2020, 20, 1073-1082.	1.4	11
36	Vero Cells as a Mammalian Cell Substrate for Human Norovirus. Viruses, 2020, 12, 439.	1.5	9

#	Article	IF	CITATIONS
37	Regulation of Mumps Virus Replication and Transcription by Kinase RPS6KB1. Journal of Virology, 2020, 94, .	1.5	3
38	A Potent Neutralizing Site III-Specific Human Antibody Neutralizes Human Metapneumovirus <i>In Vivo</i> . Journal of Virology, 2019, 93, .	1.5	25
39	Gene-edited vero cells as rotavirus vaccine substrates. Vaccine: X, 2019, 3, 100045.	0.9	12
40	Determining Immune and miRNA Biomarkers Related to Respiratory Syncytial Virus (RSV) Vaccine Types. Frontiers in Immunology, 2019, 10, 2323.	2.2	15
41	Original Antigenic Sin and Respiratory Syncytial Virus Vaccines. Vaccines, 2019, 7, 107.	2.1	12
42	Generation of H7N9-specific human polyclonal antibodies from a transchromosomic goat (caprine) system. Scientific Reports, 2019, 9, 366.	1.6	7
43	MicroRNA and Nonsense Transcripts as Putative Viral Evasion Mechanisms. Frontiers in Cellular and Infection Microbiology, 2019, 9, 152.	1.8	5
44	Role of Type I Interferon (IFN) in the Respiratory Syncytial Virus (RSV) Immune Response and Disease Severity. Frontiers in Immunology, 2019, 10, 566.	2.2	84
45	Human Norovirus: Experimental Models of Infection. Viruses, 2019, 11, 151.	1.5	36
46	Editorial: Understanding the Limitations of Current Influenza Vaccine Strategies and Future Development of More Efficacious Preventative and Therapeutic Interventions. Frontiers in Immunology, 2019, 10, 2804.	2.2	0
47	Verdinexor (KPT-335), a Selective Inhibitor of Nuclear Export, Reduces Respiratory Syncytial Virus Replication <i>In Vitro</i> . Journal of Virology, 2019, 93, .	1.5	27
48	Native Human Monoclonal Antibodies with Potent Cross-Lineage Neutralization of Influenza B Viruses. Antimicrobial Agents and Chemotherapy, 2018, 62, .	1.4	12
49	Anti-respiratory syncytial virus (RSV) G monoclonal antibodies reduce lung inflammation and viral lung titers when delivered therapeutically in a BALB/c mouse model. Antiviral Research, 2018, 154, 149-157.	1.9	36
50	An innate defense peptide BPIFA1/SPLUNC1 restricts influenza A virus infection. Mucosal Immunology, 2018, 11, 71-81.	2.7	35
51	Respiratory Syncytial Virus: Targeting the G Protein Provides a New Approach for an Old Problem. Journal of Virology, 2018, 92, .	1.5	55
52	Viral Modulation of Host Translation and Implications for Vaccine Development. , 2018, , .		0
53	Verdinexor Targeting of CRM1 is a Promising Therapeutic Approach against RSV and Influenza Viruses. Viruses, 2018, 10, 48.	1.5	23
54	Susceptibility of influenza viruses to hypothiocyanite and hypoiodite produced by lactoperoxidase in a cell-free system. PLoS ONE, 2018, 13, e0199167.	1.1	35

#	Article	IF	CITATIONS
55	MicroRNA screening identifies miR-134 as a regulator of poliovirus and enterovirus 71 infection. Scientific Data, 2017, 4, 170023.	2.4	14
56	Development of improved vaccine cell lines against rotavirus. Scientific Data, 2017, 4, 170021.	2.4	22
57	Enhanced immunogenicity following miR-155 incorporation into the influenza A virus genome. Virus Research, 2017, 235, 115-120.	1.1	18
58	Targeting the proâ€inflammatory factor CCL2 (MCPâ€1) with Bindarit for influenza A (H7N9) treatment. Clinical and Translational Immunology, 2017, 6, e135.	1.7	11
59	Respiratory syncytial virus: prospects for new and emerging therapeutics. Expert Review of Respiratory Medicine, 2017, 11, 609-615.	1.0	58
60	A Sendai virus recombinant vaccine expressing a gene for truncated human metapneumovirus (hMPV) fusion protein protects cotton rats from hMPV challenge. Virology, 2017, 509, 60-66.	1.1	11
61	MicroRNA-134 regulates poliovirus replication by IRES targeting. Scientific Reports, 2017, 7, 12664.	1.6	3
62	Vaccination with Recombinant Parainfluenza Virus 5 Expressing Neuraminidase Protects against Homologous and Heterologous Influenza Virus Challenge. Journal of Virology, 2017, 91, .	1.5	26
63	Molecular epidemiology of swine influenza A viruses in the Southeastern United States, highlights regional differences in circulating strains. Veterinary Microbiology, 2017, 211, 174-179.	0.8	21
64	Roles of Non-coding RNAs in Respiratory Syncytial Virus (RSV) Infection. Current Topics in Microbiology and Immunology, 2017, 419, 215-241.	0.7	0
65	Coated protein nanoclusters from influenza H7N9 HA are highly immunogenic and induce robust protective immunity. Nanomedicine: Nanotechnology, Biology, and Medicine, 2017, 13, 253-262.	1.7	30
66	The Central Conserved Region (CCR) of Respiratory Syncytial Virus (RSV) G Protein Modulates Host miRNA Expression and Alters the Cellular Response to Infection. Vaccines, 2017, 5, 16.	2.1	25
67	A universal mammalian vaccine cell line substrate. PLoS ONE, 2017, 12, e0188333.	1.1	16
68	Synthetic Biodegradable Microparticle and Nanoparticle Vaccines against the Respiratory Syncytial Virus. Vaccines, 2016, 4, 45.	2.1	27
69	ADAMTS5 Is a Critical Regulator of Virus-Specific T Cell Immunity. PLoS Biology, 2016, 14, e1002580.	2.6	46
70	Passive narcosis for anesthesia induction in cotton rats (Sigmodon hispidus). Lab Animal, 2016, 45, 333-337.	0.2	0
71	Development of a Zika vaccine. Expert Review of Vaccines, 2016, 15, 1083-1085.	2.0	32
72	Visible-Light-Activated Bactericidal Functions of Carbon "Quantum―Dots. ACS Applied Materials & Interfaces, 2016, 8, 10761-10766.	4.0	206

#	Article	IF	CITATIONS
73	Virologic Differences Do Not Fully Explain the Diversification of Swine Influenza Viruses in the United States. Journal of Virology, 2016, 90, 10074-10082.	1.5	3
74	Quantification of RSV Infectious Particles by Plaque Assay and Immunostaining Assay. Methods in Molecular Biology, 2016, 1442, 33-40.	0.4	7
75	Human Respiratory Syncytial Virus: An Introduction. Methods in Molecular Biology, 2016, 1442, 1-12.	0.4	12
76	MicroRNA Profiling from RSV-Infected Biofluids, Whole Blood, and Tissue Samples. Methods in Molecular Biology, 2016, 1442, 195-208.	0.4	4
77	Visible Lightâ€Induced Photoeletrochemical and Antimicrobial Properties of Hierarchical CuBi ₂ O ₄ by Facile Hydrothermal Synthesis. ChemistrySelect, 2016, 1, 1518-1524.	0.7	36
78	Production of Potent Fully Human Polyclonal Antibodies against Ebola Zaire Virus in Transchromosomal Cattle. Scientific Reports, 2016, 6, 24897.	1.6	35
79	Understanding respiratory syncytial virus (RSV) vaccine development and aspects of disease pathogenesis. Expert Review of Vaccines, 2016, 15, 173-187.	2.0	37
80	Hypothiocyanite produced by human and rat respiratory epithelial cells inactivates extracellular H1N2 influenza A virus. Inflammation Research, 2016, 65, 71-80.	1.6	21
81	Engineering Enhanced Vaccine Cell Lines To Eradicate Vaccine-Preventable Diseases: the Polio End Game. Journal of Virology, 2016, 90, 1694-1704.	1.5	35
82	MicroRNA-555 has potent antiviral properties against poliovirus. Journal of General Virology, 2016, 97, 659-668.	1.3	21
83	MicroRNA Regulation of Human Genes Essential for Influenza A (H7N9) Replication. PLoS ONE, 2016, 11, e0155104.	1.1	29
84	Antiviral Efficacy of Verdinexor In Vivo in Two Animal Models of Influenza A Virus Infection. PLoS ONE, 2016, 11, e0167221.	1.1	31
85	Layer-By-Layer Nanoparticle Vaccines Carrying the G Protein CX3C Motif Protect against RSV Infection and Disease. Vaccines, 2015, 3, 829-849.	2.1	23
86	Gammaherpesvirus infection modulates the temporal and spatial expression of SCGB1A1 (CCSP) and BPIFA1 (SPLUNC1) in the respiratory tract. Laboratory Investigation, 2015, 95, 610-624.	1.7	8
87	Repurposing Kinase Inhibitors as Antiviral Agents to Control Influenza A Virus Replication. Assay and Drug Development Technologies, 2015, 13, 638-649.	0.6	57
88	An anti-G protein monoclonal antibody treats RSV disease more effectively than an anti-F monoclonal antibody in BALB/c mice. Virology, 2015, 483, 117-125.	1.1	60
89	Interferon Lambda Upregulates IDO1 Expression in Respiratory Epithelial Cells After Influenza Virus Infection. Journal of Interferon and Cytokine Research, 2015, 35, 554-562.	0.5	62
90	Swine Influenza Virus PA and Neuraminidase Gene Reassortment into Human H1N1 Influenza Virus Is Associated with an Altered Pathogenic Phenotype Linked to Increased MIP-2 Expression. Journal of Virology, 2015, 89, 5651-5667.	1.5	7

#	Article	IF	CITATIONS
91	Differentiation and classification of bacteria using vancomycin functionalized silver nanorods array based surface-enhanced Raman spectroscopy and chemometric analysis. Talanta, 2015, 139, 96-103.	2.9	67
92	Serial passage in ducks of a low-pathogenic avian influenza virus isolated from a chicken reveals a high mutation rate in the hemagglutinin that is likely due to selection in the host. Archives of Virology, 2015, 160, 2455-2470.	0.9	5
93	Induction and Antagonism of Antiviral Responses in Respiratory Syncytial Virus-Infected Pediatric Airway Epithelium. Journal of Virology, 2015, 89, 12309-12318.	1.5	42
94	Detection of neuraminidase stalk motifs associated with enhanced N1 subtype influenza A virulence via Raman spectroscopy. Analyst, The, 2015, 140, 7748-7760.	1.7	6
95	Zinc affects miR-548n, SMAD4, SMAD5 expression in HepG2 hepatocyte and HEp-2 lung cell lines. BioMetals, 2015, 28, 959-966.	1.8	4
96	Dual Proinflammatory and Antiviral Properties of Pulmonary Eosinophils in Respiratory Syncytial Virus Vaccine-Enhanced Disease. Journal of Virology, 2015, 89, 1564-1578.	1.5	33
97	Human respiratory syncytial virus non-structural protein NS1 modifies miR-24 expression via transforming growth factor-β. Journal of General Virology, 2015, 96, 3179-3191.	1.3	27
98	Memory T Cells Generated by Prior Exposure to Influenza Cross React with the Novel H7N9 Influenza Virus and Confer Protective Heterosubtypic Immunity. PLoS ONE, 2015, 10, e0115725.	1.1	25
99	Tumor Progression Locus 2 Promotes Induction of IFNλ, Interferon Stimulated Genes and Antigen-Specific CD8+ T Cell Responses and Protects against Influenza Virus. PLoS Pathogens, 2015, 11, e1005038.	2.1	18
100	A pioneering countermeasure against measles virus. Annals of Translational Medicine, 2015, 3, S15.	0.7	1
101	Prophylaxis with a Respiratory Syncytial Virus (RSV) Anti-G Protein Monoclonal Antibody Shifts the Adaptive Immune Response to RSV rA2-line19F Infection from Th2 to Th1 in BALB/c Mice. Journal of Virology, 2014, 88, 10569-10583.	1.5	48
102	Virus-Vectored Influenza Virus Vaccines. Viruses, 2014, 6, 3055-3079.	1.5	40
103	Multiplexed screening of natural humoral immunity identifies antibodies at fine specificity for complex and dynamic viral targets. MAbs, 2014, 6, 460-473.	2.6	22
104	Drug analog inhibition of indoleamine 2,3-dioxygenase (IDO) activity modifies pattern recognition receptor expression and proinflammatory cytokine responses early during influenza virus infection. Journal of Leukocyte Biology, 2014, 96, 447-452.	1.5	14
105	Can an influenza A-based delivery system overcome current challenges associated with miRNA technology?. Future Virology, 2014, 9, 879-882.	0.9	0
106	Identification of Virulence Determinants in Influenza Viruses. Analytical Chemistry, 2014, 86, 6911-6917.	3.2	21
107	Antiviral Effects of Inhibiting Host Gene Expression. Current Topics in Microbiology and Immunology, 2014, 386, 459-477.	0.7	13
108	Verdinexor, a Novel Selective Inhibitor of Nuclear Export, Reduces Influenza A Virus Replication <i>In Vitro</i> and <i>In Vivo</i> . Journal of Virology, 2014, 88, 10228-10243.	1.5	96

#	Article	IF	CITATIONS
109	A respiratory syncytial virus (RSV) vaccine based on parainfluenza virus 5 (PIV5). Vaccine, 2014, 32, 3050-3057.	1.7	34
110	Indoleamine 2,3-Dioxygenase (IDO) Activity During the Primary Immune Response to Influenza Infection Modifies the Memory T Cell Response to Influenza Challenge. Viral Immunology, 2014, 27, 112-123.	0.6	27
111	Polymerase Discordance in Novel Swine Influenza H3N2v Constellations Is Tolerated in Swine but Not Human Respiratory Epithelial Cells. PLoS ONE, 2014, 9, e110264.	1.1	7
112	Subsisting H1N1 influenza memory responses are insufficient to protect from pandemic H1N1 influenza challenge in C57BL/6 mice. Journal of General Virology, 2013, 94, 1701-1711.	1.3	2
113	Targeting Cell Division Cycle 25 Homolog B To Regulate Influenza Virus Replication. Journal of Virology, 2013, 87, 13775-13784.	1.5	20
114	Detection and differentiation of foodborne pathogenic bacteria in mung bean sprouts using field deployable label-free SERS devices. Analyst, The, 2013, 138, 3005.	1.7	98
115	Adenovirus 36, adiposity, and bone strength in late-adolescent females. Journal of Bone and Mineral Research, 2013, 28, 489-496.	3.1	17
116	Targeting Organic Anion Transporter 3 with Probenecid as a Novel Anti-Influenza A Virus Strategy. Antimicrobial Agents and Chemotherapy, 2013, 57, 475-483.	1.4	44
117	Inhibition of indoleamine 2,3-dioxygenase enhances the T-cell response to influenza virus infection. Journal of General Virology, 2013, 94, 1451-1461.	1.3	52
118	Transmission Studies Resume for Avian Flu. Science, 2013, 339, 520-521.	6.0	34
119	Modeling Respiratory Syncytial Virus Cytopathogenesis in the Human Airway. American Journal of Respiratory and Critical Care Medicine, 2013, 188, 766-767.	2.5	4
120	Advances in and the potential of vaccines for respiratory syncytial virus. Expert Review of Respiratory Medicine, 2013, 7, 411-427.	1.0	14
121	Gain-of-Function Experiments on H7N9. Science, 2013, 341, 612-613.	6.0	24
122	A Respiratory Syncytial Virus (RSV) Anti-G Protein F(ab′) ₂ Monoclonal Antibody Suppresses Mucous Production and Breathing Effort in RSV rA2-line19F-Infected BALB/c Mice. Journal of Virology, 2013, 87, 10955-10967.	1.5	53
123	A Novel Influenza Virus Hemagglutinin-Respiratory Syncytial Virus (RSV) Fusion Protein Subunit Vaccine against Influenza and RSV. Journal of Virology, 2013, 87, 10792-10804.	1.5	8
124	siRNA Genome Screening Approaches to Therapeutic Drug Repositioning. Pharmaceuticals, 2013, 6, 124-160.	1.7	25
125	Bat cells from <i><scp>P</scp>teropus alecto</i> are susceptible to influenza <scp>A</scp> virus infection and reassortment. Influenza and Other Respiratory Viruses, 2013, 7, 900-903.	1.5	22
126	Respiratory Syncytial Virus (RSV) Modulation at the Virus-Host Interface Affects Immune Outcome and Disease Pathogenesis. Immune Network, 2013, 13, 163.	1.6	7

#	Article	IF	CITATIONS
127	Induction and Role of Indoleamine 2,3 Dioxygenase in Mouse Models of Influenza A Virus Infection. PLoS ONE, 2013, 8, e66546.	1.1	53
128	Antiviral Responses by Swine Primary Bronchoepithelial Cells Are Limited Compared to Human Bronchoepithelial Cells Following Influenza Virus Infection. PLoS ONE, 2013, 8, e70251.	1.1	16
129	Nanoparticle Vaccines Encompassing the Respiratory Syncytial Virus (RSV) G Protein CX3C Chemokine Motif Induce Robust Immunity Protecting from Challenge and Disease. PLoS ONE, 2013, 8, e74905.	1.1	46
130	Decrease in Formalin-Inactivated Respiratory Syncytial Virus (FI-RSV) Enhanced Disease with RSV G Glycoprotein Peptide Immunization in BALB/c Mice. PLoS ONE, 2013, 8, e83075.	1.1	17
131	Identification of Host Kinase Genes Required for Influenza Virus Replication and the Regulatory Role of MicroRNAs. PLoS ONE, 2013, 8, e66796.	1.1	55
132	Infectious Diseases, Vibrational Spectroscopic Approaches to Rapid Diagnostics. , 2013, , 147-169.		0
133	Host Gene Expression and Respiratory Syncytial Virus Infection. Current Topics in Microbiology and Immunology, 2013, 372, 193-209.	0.7	8
134	Therapeutic Considerations for Middle East Respiratory Syndrome Coronavirus. Journal of Antivirals & Antiretrovirals, 2013, 05, .	0.1	0
135	Pause on Avian Flu Transmission Research. Science, 2012, 335, 400-401.	6.0	58
136	Antibodies to the Central Conserved Region of Respiratory Syncytial Virus (RSV) G Protein Block RSV G Protein CX3C-CX3CR1 Binding and Cross-Neutralize RSV A and B Strains. Viral Immunology, 2012, 25, 120502120244005.	0.6	56
137	Detection and Differentiation of Avian Mycoplasmas by Surface-Enhanced Raman Spectroscopy Based on a Silver Nanorod Array. Applied and Environmental Microbiology, 2012, 78, 1930-1935.	1.4	37
138	Current Progress on Surface-Enhanced Raman Scattering Chemical/Biological Sensing. ACS Symposium Series, 2012, , 235-272.	0.5	3
139	Host gene targets for novel influenza therapies elucidated by highâ€ŧhroughput RNA interference screens. FASEB Journal, 2012, 26, 1372-1386.	0.2	52
140	Nebulized live-attenuated influenza vaccine provides protection in ferrets at a reduced dose. Vaccine, 2012, 30, 3026-3033.	1.7	20
141	Respiratory syncytial virus modifies microRNAs regulating host genes that affect virus replication. Journal of General Virology, 2012, 93, 2346-2356.	1.3	90
142	Label-Free Detection of Micro-RNA Hybridization Using Surface-Enhanced Raman Spectroscopy and Least-Squares Analysis. Journal of the American Chemical Society, 2012, 134, 12889-12892.	6.6	99
143	The use of a handheld Raman system for virus detection. Proceedings of SPIE, 2012, , .	0.8	6
144	Highly Sensitive and Transparent Surface Enhanced Raman Scattering Substrates Made by Active Coldly Condensed Ag Nanorod Arrays. Journal of Physical Chemistry C, 2012, 116, 20550-20557.	1.5	38

#	Article	IF	CITATIONS
145	MicroRNA Regulation of Human Protease Genes Essential for Influenza Virus Replication. PLoS ONE, 2012, 7, e37169.	1.1	40
146	Flexible and mechanical strain resistant large area SERS active substrates. Nanoscale, 2012, 4, 3410.	2.8	112
147	Surveillance of feral cats for influenza A virus in North Central Florida. Influenza and Other Respiratory Viruses, 2012, 6, 341-347.	1.5	7
148	Combination Therapy Using Monoclonal Antibodies against Respiratory Syncytial Virus (RSV) G Glycoprotein Protects from RSV Disease in BALB/c Mice. PLoS ONE, 2012, 7, e51485.	1.1	37
149	Infectious Diseases, Vibrational Spectroscopic Approaches to Rapid Diagnostics. , 2012, , 5382-5398.		0
150	One-step assay for detecting influenza virus using dynamic light scattering and gold nanoparticles. Analyst, The, 2011, 136, 3083.	1.7	136
151	Aerosol vaccination induces robust protective immunity to homologous and heterologous influenza infection in mice. Vaccine, 2011, 29, 2568-2575.	1.7	16
152	Comparison of the receptor binding properties of contemporary swine isolates and early human pandemic H1N1 isolates (Novel 2009 H1N1). Virology, 2011, 413, 169-182.	1.1	71
153	Passage of low-pathogenic avian influenza (LPAI) viruses mediates rapid genetic adaptation of a wild-bird isolate in poultry. Archives of Virology, 2011, 156, 565-576.	0.9	13
154	Human Metapneumovirus: Lessons Learned over the First Decade. Clinical Microbiology Reviews, 2011, 24, 734-754.	5.7	167
155	Comparative Pathology in Ferrets Infected with H1N1 Influenza A Viruses Isolated from Different Hosts. Journal of Virology, 2011, 85, 7572-7581.	1.5	27
156	Rabies Virus Expressing Dendritic Cell-Activating Molecules Enhances the Innate and Adaptive Immune Response to Vaccination. Journal of Virology, 2011, 85, 1634-1644.	1.5	88
157	Aerosol Inoculation with a Sub-lethal Influenza Virus Leads to Exacerbated Morbidity and Pulmonary Disease Pathogenesis. Viral Immunology, 2011, 24, 131-142.	0.6	22
158	Avian Influenza Viruses Infect Primary Human Bronchial Epithelial Cells Unconstrained by Sialic Acid α2,3 Residues. PLoS ONE, 2011, 6, e21183.	1.1	45
159	Identification of individual genotypes of measles virus using surface enhanced Raman spectroscopy. Analyst, The, 2010, 135, 3103.	1.7	25
160	Rapid and Sensitive Detection of Rotavirus Molecular Signatures Using Surface Enhanced Raman Spectroscopy. PLoS ONE, 2010, 5, e10222.	1.1	92
161	Detection of Mycoplasma pneumoniae in Simulated and True Clinical Throat Swab Specimens by Nanorod Array-Surface-Enhanced Raman Spectroscopy. PLoS ONE, 2010, 5, e13633.	1.1	57
162	Prophylactic Treatment with a G Glycoprotein Monoclonal Antibody Reduces Pulmonary Inflammation in Respiratory Syncytial Virus (RSV)-Challenged Nail`ve and Formalin-Inactivated RSV-Immunized BALB/c Mice. Journal of Virology, 2010, 84, 9632-9636.	1.5	64

#	Article	IF	CITATIONS
163	Respiratory Syncytial Virus F and G Proteins Induce Interleukin 1α, CC, and CXC Chemokine Responses by Normal Human Bronchoepithelial Cells. Journal of Infectious Diseases, 2010, 201, 1201-1207.	1.9	49
164	Vaccination To Induce Antibodies Blocking the CX3C-CX3CR1 Interaction of Respiratory Syncytial Virus G Protein Reduces Pulmonary Inflammation and Virus Replication in Mice. Journal of Virology, 2010, 84, 1148-1157.	1.5	87
165	Therapeutic targeting of respiratory syncytial virus G-protein. Immunotherapy, 2010, 2, 655-661.	1.0	35
166	Label-free SERS detection of microRNA based on affinity for an unmodified silver nanorod array substrate. Chemical Communications, 2010, 46, 3298.	2.2	96
167	Potent High-Affinity Antibodies for Treatment and Prophylaxis of Respiratory Syncytial Virus Derived from B Cells of Infected Patients. Journal of Immunology, 2009, 183, 6338-6345.	0.4	87
168	Treatment with respiratory syncytial virus G glycoprotein monoclonal antibody or F(ab′)2 components mediates reduced pulmonary inflammation in mice. Journal of General Virology, 2009, 90, 1119-1123.	1.3	64
169	Therapeutic Monoclonal Antibody Treatment Targeting Respiratory Syncytial Virus (RSV) G Protein Mediates Viral Clearance and Reduces the Pathogenesis of RSV Infection in BALB/c Mice. Journal of Infectious Diseases, 2009, 200, 439-447.	1.9	115
170	Respiratory Syncytial Virus Proteins Modulate Suppressors of Cytokine Signaling 1 and 3 and the Type I Interferon Response to Infection by a Toll-Like Receptor Pathway. Viral Immunology, 2009, 22, 147-161.	0.6	73
171	The host response and molecular pathogenesis associated with respiratory syncytial virus infection. Future Microbiology, 2009, 4, 279-297.	1.0	82
172	RNA Interference-Mediated Silencing of the Respiratory Syncytial Virus Nucleocapsid Defines a Potent Antiviral Strategy. Antimicrobial Agents and Chemotherapy, 2009, 53, 3952-3962.	1.4	133
173	Human Metapneumovirus Establishes Persistent Infection in the Lungs of Mice and Is Reactivated by Glucocorticoid Treatment. Journal of Virology, 2009, 83, 6837-6848.	1.5	32
174	Emerging Technologies in Nanotechnology-Based Pathogen Detection. Clinical Microbiology Newsletter, 2009, 31, 137-144.	0.4	21
175	Replication and pathogenesis associated with H5N1, H5N2, and H5N3 low-pathogenic avian influenza virus infection in chickens and ducks. Archives of Virology, 2009, 154, 1241-1248.	0.9	40
176	Fabrication and characterization of a multiwell array SERS chip with biological applications. Biosensors and Bioelectronics, 2009, 24, 3663-3670.	5.3	74
177	Quantitative Surface-Enhanced Raman Spectroscopy Based Analysis of MicroRNA Mixtures. Applied Spectroscopy, 2009, 63, 1107-1114.	1.2	61
178	Animal Models for Evaluation of Influenza Vaccines. Current Topics in Microbiology and Immunology, 2009, 333, 397-412.	0.7	31
179	Respiratory Syncytial Virus Activates Innate Immunity through Toll-Like Receptor 2. Journal of Virology, 2009, 83, 1492-1500.	1.5	233
180	Therapeutic Applications of RNAi for Silencing Virus Replication. Methods in Molecular Biology, 2009, 555, 43-61.	0.4	13

#	Article	IF	CITATIONS
181	Molecular and cellular mechanisms in the viral exacerbation of asthma. Microbes and Infection, 2008, 10, 1014-1023.	1.0	15
182	Rapid microRNA (miRNA) detection and classification via surface-enhanced Raman spectroscopy (SERS). Biosensors and Bioelectronics, 2008, 24, 917-922.	5.3	221
183	Serum Mannose-Binding Lectin Levels are Linked with Respiratory Syncytial Virus (RSV) Disease. Journal of Clinical Immunology, 2008, 28, 166-173.	2.0	24
184	Identification and classification of respiratory syncytial virus (RSV) strains by surface-enhanced Raman spectroscopy and multivariate statistical techniques. Analytical and Bioanalytical Chemistry, 2008, 390, 1551-1555.	1.9	127
185	Novel nanostructures for SERS biosensing. Nano Today, 2008, 3, 31-37.	6.2	396
186	Infectious Agent Detection With SERS-Active Silver Nanorod Arrays Prepared by Oblique Angle Deposition. IEEE Sensors Journal, 2008, 8, 863-870.	2.4	52
187	Respiratory syncytial virus (RSV) attachment and nonstructural proteins modify the type I interferon response associated with suppressor of cytokine signaling (SOCS) proteins and IFN-stimulated gene-15 (ISG15). Virology Journal, 2008, 5, 116.	1.4	83
188	An Au/Si hetero-nanorod-based biosensor for <i>Salmonella</i> detection. Nanotechnology, 2008, 19, 155502.	1.3	82
189	RNA Interference Inhibits Respiratory Syncytial Virus Replication and Disease Pathogenesis without Inhibiting Priming of the Memory Immune Response. Journal of Virology, 2008, 82, 12221-12231.	1.5	26
190	Revised model for early memory T-cell protection against respiratory virus challenge. Future Virology, 2008, 3, 533-536.	0.9	0
191	Recombinant vaccines for influenza virus. Current Opinion in Investigational Drugs, 2008, 9, 836-45.	2.3	10
192	An in vitro model of the leukocyte interactions associated with granuloma formation in Mycobacterium tuberculosis infection. Immunology and Cell Biology, 2007, 85, 160-168.	1.0	57
193	Recombinant parainfluenza virus 5 (PIV5) expressing the influenza A virus hemagglutinin provides immunity in mice to influenza A virus challenge. Virology, 2007, 362, 139-150.	1.1	60
194	Bioconjugated nanoparticle detection of respiratory syncytial virus infection. International Journal of Nanomedicine, 2007, 2, 117-124.	3.3	59
195	Respiratory Syncytial Virus G Protein and G Protein CX3C Motif Adversely Affect CX3CR1+ T Cell Responses. Journal of Immunology, 2006, 176, 1600-1608.	0.4	127
196	Rapid and Sensitive Detection of Respiratory Virus Molecular Signatures Using a Silver Nanorod Array SERS Substrate. Nano Letters, 2006, 6, 2630-2636.	4.5	578
197	Counting Single Native Biomolecules and Intact Viruses with Color-Coded Nanoparticles. Analytical Chemistry, 2006, 78, 1061-1070.	3.2	140
198	Perspective on the host response to human metapneumovirus infection: what can we learn from respiratory syncytial virus infections?. Microbes and Infection, 2006, 8, 285-293.	1.0	31

#	Article	IF	CITATIONS
199	Respiratory Syncytial Virus (RSV) Infects Neuronal Cells and Processes That Innervate the Lung by a Process Involving RSV G Protein. Journal of Virology, 2006, 80, 537-540.	1.5	54
200	Monoclonal antibodies to SARS-associated coronavirus (SARS-CoV): Identification of neutralizing and antibodies reactive to S, N, M and E viral proteins. Journal of Virological Methods, 2005, 128, 21-28.	1.0	53
201	The Immune Response to Human Metapneumovirus Is Associated with Aberrant Immunity and Impaired Virus Clearance in BALB/c Mice. Journal of Virology, 2005, 79, 5971-5978.	1.5	82
202	Cytokines and Respiratory Syncytial Virus Infection. Proceedings of the American Thoracic Society, 2005, 2, 147-149.	3.5	71
203	Real-Time Detection of Virus Particles and Viral Protein Expression with Two-Color Nanoparticle Probes. Journal of Virology, 2005, 79, 8625-8628.	1.5	87
204	The Brume Surrounding Respiratory Syncytial Virus Persistence. American Journal of Respiratory and Critical Care Medicine, 2004, 169, 778-779.	2.5	23
205	Human Metapneumovirus Persists in BALB/c Mice despite the Presence of Neutralizing Antibodies. Journal of Virology, 2004, 78, 14003-14011.	1.5	103
206	Anti–G Protein Antibody Responses to Respiratory Syncytial Virus Infection or Vaccination Are Associated with Inhibition of G Protein CX3Câ€CX3CR1 Binding and Leukocyte Chemotaxis. Journal of Infectious Diseases, 2004, 190, 1936-1940.	1.9	41
207	Pathogenesis of Respiratory Syncytial Virus Infection. Viral Immunology, 2004, 17, 165-181.	0.6	93
208	Serological cross-reactivity of members of the Metapneumovirus genus. Virus Research, 2004, 105, 67-73.	1.1	18
209	Pulmonary delivery of respiratory syncytial virus DNA vaccines using macroaggregated albumin particles. Vaccine, 2004, 22, 2248-2260.	1.7	17
210	Prior airway exposure to allergen increases virus-induced airway hyperresponsiveness. Journal of Allergy and Clinical Immunology, 2003, 112, 861-869.	1.5	46
211	CD40 ligand (CD154) improves the durability of respiratory syncytial virus DNA vaccination in BALB/c mice. Vaccine, 2003, 21, 2964-2979.	1.7	26
212	The G Glycoprotein of Respiratory Syncytial Virus Depresses Respiratory Rates through the CX3C Motif and Substance P. Journal of Virology, 2003, 77, 6580-6584.	1.5	81
213	Enhanced Disease and Pulmonary Eosinophilia Associated with Formalin-Inactivated Respiratory Syncytial Virus Vaccination Are Linked to G Glycoprotein CX3C-CX3CR1 Interaction and Expression of Substance P. Journal of Virology, 2003, 77, 9831-9844.	1.5	109
214	Role of Cytokines in the Development and Maintenance of Memory T Cells During Respiratory Viral Infection. Current Pharmaceutical Design, 2003, 9, 51-59.	0.9	5
215	The Failure of Interleukin-10–deficient Mice to Develop Airway Hyperresponsiveness Is Overcome by Respiratory Syncytial Virus Infection in Allergen–sensitized/challenged Mice. American Journal of Respiratory and Critical Care Medicine, 2002, 165, 824-831.	2.5	50
216	Peripheral Blood Mononuclear Cells from Infants Hospitalized Because of Respiratory Syncytial Virus Infection Express T Helper–1 and T Helper–2 Cytokines and CC Chemokine Messenger RNA. Journal of Infectious Diseases, 2002, 185, 1388-1394.	1.9	77

#	Article	IF	CITATIONS
217	Neutralizing Anti-F Glycoprotein and Anti-Substance P Antibody Treatment Effectively Reduces Infection and Inflammation Associated with Respiratory Syncytial Virus Infection. Journal of Virology, 2002, 76, 6873-6881.	1.5	31
218	Substance P receptor expression on lymphocytes is associated with the immune response to respiratory syncytial virus infection. Journal of Neuroimmunology, 2002, 129, 141-153.	1.1	37
219	Involvement of Toll-Like Receptor 4 in Innate Immunity to Respiratory Syncytial Virus. Journal of Virology, 2001, 75, 10730-10737.	1.5	447
220	CD4+ T Cell Frequencies and Th1/Th2 Cytokine Patterns Expressed in the Acute and Memory Response to Respiratory Syncytial Virus I-Ed-Restricted Peptides. Cellular Immunology, 2001, 207, 59-71.	1.4	15
221	CX3C chemokine mimicry by respiratory syncytial virus G glycoprotein. Nature Immunology, 2001, 2, 732-738.	7.0	380
222	Pattern recognition receptors TLR4 and CD14 mediate response to respiratory syncytial virus. Nature Immunology, 2000, 1, 398-401.	7.0	1,482
223	Respiratory Syncytial Virus G and/or SH Glycoproteins Modify CC and CXC Chemokine mRNA Expression in the BALB/c Mouse. Journal of Virology, 2000, 74, 6227-6229.	1.5	89
224	Respiratory Syncytial Virus Infection and G and/or SH Protein Expression Contribute to Substance P, Which Mediates Inflammation and Enhanced Pulmonary Disease in BALB/c Mice. Journal of Virology, 2000, 74, 1614-1622.	1.5	77
225	CD40 Ligand (CD154) Enhances the Th1 and Antibody Responses to Respiratory Syncytial Virus in the BALB/c Mouse. Journal of Immunology, 2000, 164, 5913-5921.	0.4	53
226	TH1- AND TH2-TYPE CYTOKINE EXPRESSION BY ACTIVATED TLYMPHOCYTES FROM THE LUNG AND SPLEEN DURING THE INFLAMMATORY RESPONSE TO RESPIRATORY SYNCYTIAL VIRUS. Cytokine, 2000, 12, 801-807.	1.4	28
227	Respiratory Syncytial Virus G and/or SH Protein Alters Th1 Cytokines, Natural Killer Cells, and Neutrophils Responding to Pulmonary Infection in BALB/c Mice. Journal of Virology, 1999, 73, 7099-7107.	1.5	145
228	Reconstitution of Early Lymphoid Proliferation and Immune Function in Jak3-Deficient Mice by Interleukin-3. Blood, 1999, 94, 1906-1914.	0.6	21
229	Reconstitution of Early Lymphoid Proliferation and Immune Function in Jak3-Deficient Mice by Interleukin-3. Blood, 1999, 94, 1906-1914.	0.6	11
230	Reconstitution of early lymphoid proliferation and immune function in Jak3-deficient mice by interleukin-3. Blood, 1999, 94, 1906-14.	0.6	5
231	Forced degradation of Fas inhibits apoptosis in adenovirus-infected cells. Nature, 1998, 392, 726-730.	13.7	196
232	Influenza Virus (Orthomyxovirus), Infection and Immunity. , 1998, , 1385-1387.		0
233	Cytotoxic T-Lymphocyte Precursor Frequencies in BALB/c Mice after Acute Respiratory Syncytial Virus (RSV) Infection or Immunization with a Formalin-Inactivated RSV Vaccine. Journal of Virology, 1998, 72, 8971-8975.	1.5	22
234	Antiviral cytotoxic activity across a species barrier in mixed xenogeneic chimeras: functional restriction to host MHC. Journal of Immunology, 1998, 160, 3790-6.	0.4	15

#	Article	IF	CITATIONS
235	Pathogenesis of an Infectious Mononucleosis-like Disease Induced by a Murine γ-Herpesvirus: Role for a Viral Superantigen?. Journal of Experimental Medicine, 1997, 185, 1641-1650.	4.2	161
236	Effector CD4+ and CD8+ T-cell mechanisms in the control of respiratory virus infections. Immunological Reviews, 1997, 159, 105-117.	2.8	407
237	Tuning into immunological dissonance: an experimental model for infectious mononucleosis. Current Opinion in Immunology, 1997, 9, 477-483.	2.4	71
238	The cytotoxic T-lymphocyte response to Sendai virus is unimpaired in the absence of gamma interferon. Journal of Virology, 1997, 71, 1906-1910.	1.5	33
239	Modification of the Sendai virus-specific antibody and CD8+ T-cell responses in mice homozygous for disruption of the interleukin-4 gene. Journal of Virology, 1997, 71, 2518-2521.	1.5	17
240	Bone marrow can function as a lymphoid organ during a primary immune response under conditions of disrupted lymphocyte trafficking. Journal of Immunology, 1997, 158, 3716-20.	0.4	63
241	CD8+ T cells clear influenza virus by perforin or Fas-dependent processes. Journal of Immunology, 1997, 159, 5197-200.	0.4	376
242	Establishment and Persistence of Virus-Specific CD4+ and CD8+ T Cell Memory. Immunological Reviews, 1996, 150, 23-44.	2.8	152
243	Lack of IL-4-induced Th2 response and IgE class switching in mice with disrupted State6 gene. Nature, 1996, 380, 630-633.	13.7	1,223
244	Requirement for Stat4 in interleukin-12-mediated responses of natural killer and T cells. Nature, 1996, 382, 171-174.	13.7	1,059
245	Immune CD4+ T cells promote the clearance of influenza virus from major histocompatibility complex class II -/- respiratory epithelium. Journal of Virology, 1996, 70, 1288-1291.	1.5	85
246	The role of human adenovirus early region 3 proteins (gp19K, 10.4K, 14.5K, and 14.7K) in a murine pneumonia model. Journal of Virology, 1996, 70, 2431-2439.	1.5	80
247	Cytokine production in the immune response to murine gammaherpesvirus 68. Journal of Virology, 1996, 70, 3264-3268.	1.5	71
248	Recombinant polyepitope vaccines for the delivery of multiple CD8 cytotoxic T cell epitopes. Journal of Immunology, 1996, 157, 822-6.	0.4	89
249	Quantitative analysis of the influenza virus-specific CD4+ T cell memory in the absence of B cells and Ig. Journal of Immunology, 1996, 157, 2947-52.	0.4	118
250	Defective Lymphoid Development in Mice Lacking Jak3. Science, 1995, 270, 800-802.	6.0	620
251	Temporal loss of the activated L-selectin-low phenotype for virus-specific CD8+ memory T cells. Journal of Immunology, 1995, 154, 5870-5.	0.4	111
252	Laser light suicide of proliferating virus-specific CD8+ T cells in an in vivo response. Journal of Immunology, 1995, 155, 3719-21.	0.4	19

#	Article	IF	CITATIONS
253	Characteristics of the influenza virus-specific CD8+ T cell response in mice homozygous for disruption of the H-2lAb gene. Journal of Immunology, 1995, 155, 2955-9.	0.4	96
254	Recruitment and proliferation of CD8+ T cells in respiratory virus infections. Journal of Immunology, 1995, 154, 6013-21.	0.4	108
255	CD8+ T-cell memory to viruses. Current Opinion in Immunology, 1994, 6, 545-552.	2.4	97
256	Evasion of Host Immune Responses by Tumours and Viruses. Novartis Foundation Symposium, 1994, 187, 245-270.	1.2	2
257	Deletion mutation analysis of the adenovirus type 2 E3-gp19K protein: identification of sequences within the endoplasmic reticulum lumenal domain that are required for class I antigen binding and protection from adenovirus-specific cytotoxic T lymphocytes. Journal of Virology, 1993, 67, 5289-5298.	1.5	60
258	Stress alters immune function and disease resistance in chinook salmon (Oncorhynchus) Tj ETQq0 0 0 rgBT /Ove	≥rlock 10 T	f 50 542 Td (

259	Cortisol mediated suppression of salmonid lymphocyte responses invitro. Developmental and Comparative Immunology, 1987, 11, 565-576.	1.0	134
260	Primary in vitro stimulation of antibody production by rainbow trout lymphocytes. Veterinary Immunology and Immunopathology, 1986, 12, 29-38.	0.5	31